Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19
Aim. To evaluate the changes of the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in patients with sinus tachycardia after coronavirus disease 2019 (COVID-19) during ivabradine monotherapy or in combination with β-blockers (BBs) compared to BB monotherapy.Material and methods. T...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2023-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/3485 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030450414714880 |
|---|---|
| author | V. I. Podzolkov A. E. Bragina A. I. Tarzimanova T. S. Vargina E. S. Ogibenina I. I. Shvedov E. E. Bykova A. A. Ivannikov |
| author_facet | V. I. Podzolkov A. E. Bragina A. I. Tarzimanova T. S. Vargina E. S. Ogibenina I. I. Shvedov E. E. Bykova A. A. Ivannikov |
| author_sort | V. I. Podzolkov |
| collection | DOAJ |
| description | Aim. To evaluate the changes of the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in patients with sinus tachycardia after coronavirus disease 2019 (COVID-19) during ivabradine monotherapy or in combination with β-blockers (BBs) compared to BB monotherapy.Material and methods. This randomized comparative study included 90 patients discharged from the hospital after an acute period of COVID-19. The main group (n=60) included patients who received ivabradine monotherapy or in combination with BB in addition to standard therapy, while the control group (n=30) — standard therapy in combination with BB. The follow-up period lasted 24 weeks. Serum NT-proBNP concentration was determined by enzyme immunoassay at the first and last visit (0 and 24 weeks). Statistical processing was performed using STATISTICA 8.0 software. The level of statistical significance was p<0,05.Results. A significant decrease in heart rate (HR) and NT-proBNP concentration was noted in both groups. The achievement rate of maximum recommended BB doses was 9,1% in the main group and 20% in the control group. Among individuals who did not achieve the maximum recommended doses of BB, the HR and NT-proBNP concentration were significantly higher in the control group as follows: 72 [66; 75] vs 68 [66; 75] bpm (p=0,028) and 55,5 [47,3; 88,8] vs 43,3 [31,0; 55,5] pg/ml, respectively (p=0,041).Conclusion. We showed that therapy with ivabradine and betablockers helps to reduce the level of NT-proBNP against the background of HR decrease in patients after COVID-19, and ivabradine allows to achieve a more pronounced decrease in heart rate and NT-proBNP level in patients with failure to achieve the maximum recommended BB doses. |
| format | Article |
| id | doaj-art-b1ab51f8315f4e3e97105bb8d2ffa999 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2023-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-b1ab51f8315f4e3e97105bb8d2ffa9992025-08-20T02:59:12Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252023-01-01211210.15829/1728-8800-2022-34852600Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19V. I. Podzolkov0A. E. Bragina1A. I. Tarzimanova2T. S. Vargina3E. S. Ogibenina4I. I. Shvedov5E. E. Bykova6A. A. Ivannikov7I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityAim. To evaluate the changes of the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration in patients with sinus tachycardia after coronavirus disease 2019 (COVID-19) during ivabradine monotherapy or in combination with β-blockers (BBs) compared to BB monotherapy.Material and methods. This randomized comparative study included 90 patients discharged from the hospital after an acute period of COVID-19. The main group (n=60) included patients who received ivabradine monotherapy or in combination with BB in addition to standard therapy, while the control group (n=30) — standard therapy in combination with BB. The follow-up period lasted 24 weeks. Serum NT-proBNP concentration was determined by enzyme immunoassay at the first and last visit (0 and 24 weeks). Statistical processing was performed using STATISTICA 8.0 software. The level of statistical significance was p<0,05.Results. A significant decrease in heart rate (HR) and NT-proBNP concentration was noted in both groups. The achievement rate of maximum recommended BB doses was 9,1% in the main group and 20% in the control group. Among individuals who did not achieve the maximum recommended doses of BB, the HR and NT-proBNP concentration were significantly higher in the control group as follows: 72 [66; 75] vs 68 [66; 75] bpm (p=0,028) and 55,5 [47,3; 88,8] vs 43,3 [31,0; 55,5] pg/ml, respectively (p=0,041).Conclusion. We showed that therapy with ivabradine and betablockers helps to reduce the level of NT-proBNP against the background of HR decrease in patients after COVID-19, and ivabradine allows to achieve a more pronounced decrease in heart rate and NT-proBNP level in patients with failure to achieve the maximum recommended BB doses.https://cardiovascular.elpub.ru/jour/article/view/3485novel coronavirus infectioncovid-19post-covid tachycardiasinus tachycardiaivabradinent-probnpnatriuretic peptidesinoatrial cell if channel blocker |
| spellingShingle | V. I. Podzolkov A. E. Bragina A. I. Tarzimanova T. S. Vargina E. S. Ogibenina I. I. Shvedov E. E. Bykova A. A. Ivannikov Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 Кардиоваскулярная терапия и профилактика novel coronavirus infection covid-19 post-covid tachycardia sinus tachycardia ivabradine nt-probnp natriuretic peptide sinoatrial cell if channel blocker |
| title | Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 |
| title_full | Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 |
| title_fullStr | Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 |
| title_full_unstemmed | Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 |
| title_short | Changes in NT-proBNP levels in patients with sinus tachycardia after COVID-19 |
| title_sort | changes in nt probnp levels in patients with sinus tachycardia after covid 19 |
| topic | novel coronavirus infection covid-19 post-covid tachycardia sinus tachycardia ivabradine nt-probnp natriuretic peptide sinoatrial cell if channel blocker |
| url | https://cardiovascular.elpub.ru/jour/article/view/3485 |
| work_keys_str_mv | AT vipodzolkov changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT aebragina changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT aitarzimanova changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT tsvargina changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT esogibenina changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT iishvedov changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT eebykova changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 AT aaivannikov changesinntprobnplevelsinpatientswithsinustachycardiaaftercovid19 |